Eupraxia Pharmaceuticals, Inc. (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals Inc., a clinical-stage biotech firm focused on long-lasting drug delivery technologies, announced its participation at the upcoming Bloom Burton & Co. Healthcare Investor Conference. With their proprietary Diffusphere™ technology, the company successfully completed a Phase 2b trial for an osteoarthritis knee pain treatment, and is expanding its research into gastrointestinal disease treatments and other areas of high medical need. The presentation by Eupraxia’s CEO is scheduled for April 16th, 2024, and will include discussions on their latest clinical trials and future development plans.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
